United States· US:0074-0039_07f98869-6203-4e8c-b576-2ba8f0a159d7
Orilissa
A elagolix product containing elagolix sodium, registered in United States by AbbVie Inc.. The same ATC class is registered in 2 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Elagolix is registered in 2 of 19 countries.
Countries holding a registration under ATC H01CC03 (elagolix), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 1 of them publish a price we can compare per daily dose
Elagolix · ATC H01CC03
2 / 19 countries
- Canada
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ELAGOLIX SODIUM
- Manufacturer
- AbbVie Inc.
- Country
- United States (US)
- ATC code
- H01CC03
- ATC class
- Elagolix
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc110074-0039-14
- ndc110074-0039-56
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
399 interactions on record for elagolix.
Graded by severity as the source publishes them — 49 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Elagolix · interactions on record
399 records
- 49 severe
- 334 moderate
- 16 minor
Most severe, free to view
- LonafarnibA16AX20severe
- EdoxabanB01AF03severe
- BerotralstatB06AC06severe
- ConivaptanC03XA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Elagolix in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d5e5df8a-2aa6-4c05-9f09-963000a11800 GET /v1/drugs/d5e5df8a-2aa6-4c05-9f09-963000a11800?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "200",
"substance": "ELAGOLIX SODIUM",
"productndc": "0074-0039",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA210450",
"marketing_category": "NDA"
}See everything about elagolix.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.